EP-4739360-A1 - IMPROVED WOUND DRESSING AND METHOD TO PREPARE IT

Abstract

The present invention relates to a wound dressing comprising a polymeric support having a coating of a polymer network comprising a poly-(4-styrenesulfonic acid-co-maleic acid) (PSS-MA) component covalently bonded to at least one of an uncharged polymer component and a non-polymeric crosslinker component thereby forming the polymer network, wherein the PSS-MA5 component comprises sulfonate groups, and a method to prepare it.

Inventors

• FREUDENBERG, UWE
• SCHIRMER, Lucas
• ATALLAH, Passant
• KÜHN, Sebastian
• WERNER, CARSTEN

Assignees

• ResCure GmbH

Dates

Publication Date

20260513

Application Date

20240705

Claims (15)

1. 1. A wound dressing comprising a polymeric support having a coating of a polymer network, the polymer network comprising at least one poly-(4-styrenesulfonic acid-co- maleic acid) component covalently bonded to at least one of at least one uncharged polymer component and at least one non-polymeric cross-linking component thereby forming the polymer network, wherein the at least one poly-(4-styrenesulfonic acid-co- maleic acid) component comprises sulfonate groups.
2. 2. The wound dressing of claim 1, wherein the polymer network is a synthetic polymer network.
3. 3. The wound dressing of claim 1 or 2, wherein the polymer network is hydratable.
4. 4. The wound dressing of any one of the preceding claims, wherein the at least one uncharged polymer component is selected from the group consisting of polyethylene glycol) (PEG) component, poly (2-oxazoline) (POX) component, polyvinylpyrrolidone (PVP) component, poly(vinyl alcohol) (PVA) component, polyacrylamide (PAM) component, and combinations thereof.
5. 5. The wound dressing according to any one of the preceding claims, wherein the at least one uncharged polymer component is a poly(ethylene glycol) component, in particular a linear or multi-arm, in particular four- or eight-arm, polyethylene glycol) component.
6. 6. The wound dressing of any one of the preceding claims, wherein the at least one non- polymeric cross-linking component is selected from the group consisting of ethylenediamine, propylenediamine (1,3 -diaminopropane), butane- 1,4-diamine, pentane-l,5-diamine (cadaverine), hexamethylene-l,6-diamine oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, N-(2-aminoethyl) maleimide, enzymatically cleavable peptides, and combinations thereof.
7. 7. The wound dressing according to any one of the preceding claims, wherein the polymeric support is a nonwoven fabric, a woven fabric, a knitted fabric, a mesh, a fiber, a fiber mesh, a foam, in particular a polymeric foam, or a perforated film.
8. 8. The wound dressing according to any one of the preceding claims, wherein the polymeric support is made of a synthetic polymer, in particular polyester, polyamide, cellulose, polyurethane, silicone polymer or polyethylene.
9. 9. The wound dressing according to any one of the preceding claims, wherein the wound dressing comprises a swellable polymer, in particular CMC, pectin or gelatin.
10. 10. The wound dressing according to any one of the preceding claims, wherein the mesh has a mesh size 500 pm to 2 mm.
11. 11. The wound dressing according to any of the preceding claims, wherein the wound dressing, in particular the coating, is non-adhesive.
12. 12. The wound dressing according to any one of the preceding claims, wherein the wound dressing comprises at least one anti-microbial agent.
13. 13. The wound dressing according to any one of the preceding claims for use in a therapeutic method for treating wounds, in particular wounds of the skin or mucosa, in particular acute or chronic wounds, in particular diabetic wounds, in particular lower leg ulcers, foot ulcers and pressure ulcers.
14. 14. The wound dressing according to any one of the preceding claims for use in a therapeutic method for treating wounds in the exudation, granulation or epithelialization phase.
15. 15. A method for producing a wound dressing, in particular according to any one of claims 1 to 14, comprising the following method steps: a) providing at least one polymeric support, poly-(4-styrenesulfonic acid-co-maleic acid) and at least one uncharged polymer, in particular a functionalized uncharged polymer, or/and at least one non-polymeric crosslinker molecule, and optionally further components, in particular a reaction medium, b) mixing the uncharged polymer or non-polymeric crosslinker molecule with the poly- (4-styrenesulfonic acid-co-maleic acid), preferably in a reaction medium; and c) applying the mixture obtained in step b) to the polymeric support, thereby forming a polymer network of at least one poly-(4-styrenesulfonic acid-co-maleic acid) component and the at least one uncharged polymer component or/and a non-polymeric crosslinking component, so as to coat the polymeric support and obtain the wound dressing.

Description

DESCRIPTION Improved wound dressing and method to prepare it The present invention relates to a wound dressing comprising a polymeric support having a coating of a polymer network comprising a poly-(4-styrenesulfonic acid-co-maleic acid) component covalently bonded to at least one of an uncharged polymer component and a non-polymeric crosslinking component thereby forming the polymer network, wherein the PSS-MA component comprises sulfonate groups, and a method to prepare it. In Germany, more than 2.7 million patients suffer from chronic, non-healing wounds. The treatment of these wounds can take months to years and requires frequent visits to the doctor and nursing care. With an aging population and increasing incidence of diabetes and obesity, many more patients will suffer from hard-to-heal wounds in the future. The main cause of delayed wound healing is a prolonged and intensified inflammatory phase, which prevents the onset of healing. Accordingly, a multitude of various therapeutic applications have been developed so as to effectively cure wounds. EP 1 718 257 Bl discloses a multi layered wound dressing for highly exudating wounds, which includes a transmission layer having high moisture vapor transmission rate, absorbent core, and a wound contacting layer. EP 1 988 909 Bl discloses a hydrogel composition or aqueous solution useful in the treatment of inflammation of the skin or mucosa and as a dermatological product, which comprises poly(ethylene glycol) having specific molecular weight. EP 2 736 486 Al discloses a composition useful for treating a wound, which comprises a pharmaceutically acceptable carrier, an effective amount of an active ingredient of inorganic solids, and an antimicrobial biguanide compound. EP 2 742 997 Bl discloses a carrier used for for instance inflammatory cytokine adsorption, which comprises high molecular com-pound(s) having two or more repeating units containing aromatic ring which is covalently bonded through specific structure. WO 2021/198464 Al discloses a hydrogel-based wound dressing formulation useful for treating wound, which comprises a copolymer of monomers with at least one covalently linked multifunctional group, and a source of nitrite and/or nitrate. WO 2021/212154 Al discloses a wound dressing useful for treating wound, which comprises a substrate having first surface and second surface comprising a sulfonated polymeric layer containing sulfonated polymer. The known technologies often use specific substances which are classified as pharmaceuticals and thus frequently cause from side-effects and need to be admitted in costly and time-consuming proceedings by the competent drug authorities prior to use. Other technologies do not exert the desired wound healing effects in a satisfactory manner or are complicated and expensive in production, structure and/or use. Thus, there is an urgent need to provide means and methods to improve wound healing, in particular to allow a rapid wound healing, in particular with a reduced inflammatory phase, in particular in a cost-effective and simple manner, in particular wherein the means and methods do not rely on the use of pharmaceutically active agents. The technical problem underlying the present invention therefore is to overcome the aforementioned disadvantages. Thus, the technical problem underlying the present invention is in particular to provide means and methods to improve the wound healing process in subjects in need thereof, in particular humans and animals, in particular means and methods which allow a faster wound healing and reduce the duration and/or intensity of the inflammatory phase, in particular wherein the means and methods do not rely on the use of pharmaceutically active agents. Preferably, such means and methods should reduce pain and discomfort of the patients during its use and also during and after removal of the wound dressing from the wound. The technical problem is solved by the teaching of the present invention, in particular the teaching as specified in the independent and dependent claims as well as in the present description. Thus, the present invention in particular provides a wound dressing comprising a polymeric support having a coating of a polymer network, the polymer network comprising at least one poly- (4-styrenesulfonic acid-co-maleic acid) (in the following also termed PSS-MA) component covalently bonded to at least one of at least one uncharged polymer component and at least one non-polymeric crosslinking component thereby forming the polymer network, wherein the PSS- MA component comprises sulfonate groups. Thus, the present invention in particular provides a wound dressing comprising a polymeric support having a coating of a polymer network, the polymer network comprising at least one poly PSS-MA component covalently bonded to at least one of at least one uncharged polymer component and at least one non-polymeric crosslinking component thereby forming the polymer network, w